Genmab — November 2020

[peter12]

Judith also mentioned CR's at the cc ?

[peter12]

And as disclosed in the abstract, by the time of the cut, the median follow-up was 8.3 months, and 25 patients were still ongoing. And I think that with this, I give you a signal, that 25 patients were still ongoing. And if you look at the data again at the tail, in above 48 milligrams for the DLBCL from 7 patients, the ORR was 100%; CR, 28%; 72% PRs, and those patients were ongoing. So – and the FPL, same thing, above 12. And the cut is arbitrary,

[Bulder]

det er epco Peter

[peter12]

ok tak

[E_L]

on P20 of the presentation , fig A, the best change in SoD from baseline =-100%; does that mean the tumor disappeared?

[E_L]

should we conclude that Colorectal cancer and Ovarian cancer will not continue to the expansion phase?

[Bulder]

looks like it, both Q

[E_L]

what is it then that you where hoping for / expecting?

[GeorgeBest]

Thanks E L for the fantastic job you are doing

[gdn55]

Ditto her. Tak

[E_L]

I did - and no need to say thanks.

[E_L]

but seriously curious what people where expecting/ why they are disapointed. We have seen these sort of early data sets many times before now, it ususally isn't more then this

[GeorgeBest]

Yes, I must admit, I got carried away with Jans words again again...;-)

[GeorgeBest]

But I am sure they will deliver again

[AaBforever]

@E L What do you expect we will hear on fridag 13.?

[GeorgeBest]

Jan always points out Genmabs abilities to combine bispecific antibodies via robotics. Any idea why other Pharma companies can‘t copy?

[GeorgeBest]

He says they can produce thousands of samples in the same time as competitors produce a handful!

[Bulder]

Hopefully an assessment of the quality of efficacy. That's where I'm a little sceptic maybe. But we'll also soon see assessments from the medical world. Looking forward to that.

[Bulder]

I'm not worried of safety at all.

[gdn55]

Måske derfor man skal beholde Genmab, eller købe inden de bliver købt